
ChondroFiller injection safety and side effects
ChondroFiller injection's documented complication rate sits at approximately 0%, with reoperation rates of 3–8% compared with 41% for microfracture and 37% for ACI procedures.
London Cartilage Clinic
Explore expert articles on cartilage care, regenerative treatments, and practical recovery advice from our specialist team.

ChondroFiller injection's documented complication rate sits at approximately 0%, with reoperation rates of 3–8% compared with 41% for microfracture and 37% for ACI procedures.

Stem cells injected into the knee are washed away by synovial fluid within hours; ChondroFiller, a collagen scaffold that self-gels in place, traps the patient's own marrow cells in the defect long enough to regenerate cartilage.

Adult articular cartilage has no blood supply and depends entirely on movement to draw oxygen and nutrients from synovial fluid — the compression-and-release cycle of loading acts like a sponge squeezed under water. Six weeks of structured physiotherapy nearly halves functional impairment scores in grades I–III knee osteoarthritis.

Hip cartilage lacks blood supply; once damaged, stress concentrates at the defect edge, widening the lesion in a self-reinforcing cycle that leads inevitably to bone-on-bone contact and osteoarthritis unless treated.

ChondroFiller is the same collagen scaffold in both the UK and Germany, but the UK delivers it as a 30–45-minute ultrasound-guided outpatient injection with same-day discharge, whilst Germany uses arthroscopic surgery under anaesthesia requiring post-operative immobilisation and months of physiotherapy.

MACI requires two operations — arthroscopic biopsy, four-to-eight-week cell culture, and implantation — yet two-thirds of patients never reach Stage 2 because the initial arthroscopic procedure alone resolves cartilage symptoms.